Cerus (NASDAQ:CERS) Stock Passes Above 200 Day Moving Average – Time to Sell?

Cerus Corporation (NASDAQ:CERS)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.76 and traded as high as $2.58. Cerus shares last traded at $2.56, with a volume of 1,788,851 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CERS. TD Cowen reiterated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.00.

Cerus Stock Up 3.6%

The company’s 50-day simple moving average is $2.26 and its two-hundred day simple moving average is $1.76. The firm has a market capitalization of $491.75 million, a P/E ratio of -32.00 and a beta of 1.52. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.89 and a quick ratio of 1.29.

Institutional Trading of Cerus

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its position in Cerus by 28.8% in the fourth quarter. Invesco Ltd. now owns 309,168 shares of the biotechnology company’s stock worth $637,000 after buying an additional 69,087 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Cerus by 48.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 53,028 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 17,336 shares in the last quarter. Engineers Gate Manager LP increased its holdings in Cerus by 4.7% in the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 6,415 shares in the last quarter. Kotler Kevin bought a new stake in Cerus during the 4th quarter worth approximately $2,084,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Cerus by 19.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 111,048 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 17,770 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.